Affiliation:
1. Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, CO 80204, USA
Abstract
Aims: Xtampza® ER (Collegium Pharmaceutical, MA, USA) is an abuse-deterrent formulation (ADF) of oxycodone intended to deter tampering for use by unintended routes of administration. We assessed whether Xtampza ER exposures were less likely to result in severe medical outcomes relative to other opioid analgesic exposures. Materials & methods: Exposures reported to participating poison centers between 2016 and 2021 inclusive that were followed to a known medical outcome were analyzed. Xtampza ER was compared with other ADF opioids, non-ADF extended-release opioids, single-entity oxycodone immediate-release, unspecified oxycodone and unspecified morphine. Results & conclusion: No Xtampza ER exposures involved unintended routes of administration. Xtampza ER exposures were less likely to be abuse, misuse or suspected suicidal, and medical outcomes were less severe than comparators.
Reference23 articles.
1. CDC. US opioid dispensing rate maps (2022). www.cdc.gov/drugoverdose/rxrate-maps/index.html
2. Administration. (2022). Key substance use and mental health indicatorsin the United States: Results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. (2022). www.samhsa.gov/data/report/2021-nsduh-annual-national-report
3. CDC. Provisional drug overdose death counts (2023). www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
4. US FDA. Abuse-deterrent opioids – evaluation and labeling: guidance for industry. 1–29 (2015) (Online). www.fda.gov/regulatory-information/search-fda-guidance-documents/abuse-deterrent-opioids-evaluation-and-labeling
5. Nonmedical Use of Xtampza® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-World Data from the Addiction Severity Index-Multimedia Version (ASI-MV®)